{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:57:29Z","timestamp":1761764249247,"version":"build-2065373602"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2012,1,17]],"date-time":"2012-01-17T00:00:00Z","timestamp":1326758400000},"content-version":"vor","delay-in-days":4705,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[1999,3]]},"abstract":"<jats:p>Tolterodine is a nonsubtype selective antimuscarinic agent recently approved as therapy in patients with overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence. It acts by muscarinic receptor blockade in the bladder wall and detrusor muscle. Despite short terminal disposition half\u2010lives of 2\u20133 and 3\u20134 hours for tolterodine and its active 5\u2010hydroxy metabolite, respectively, twice\/day dosing is effective due to the drug's prolonged pharmacodynamic effects. Dosage adjustment is recommended in the presence of hepatic impairment and during concurrent therapy with drugs that inhibit cytochrome P450 2D6 and 3A4 isozymes. Tolterodine significantly reduces clinically relevant end points such as number of micturitions and number of incontinence episodes\/day. In general, it is superior to placebo and equivalent to oxybutynin in this regard. As might be expected from its pharmacologic profile, the principal adverse effects of the drug are anticholinergic. In clinical trials, tolterodine was tolerated significantly better than oxybutynin. Its relative merits as a first\u2010 or second\u2010line agent for patients intolerant of oxybutynin are unclear. Until pharmacoeconomic analyses are conducted that clearly justify use of this more expensive agent, tolterodine is perhaps best reserved for patients who are intolerant of or fail oxybutynin therapy.<\/jats:p>","DOI":"10.1592\/phco.19.4.267.30943","type":"journal-article","created":{"date-parts":[[2004,4,27]],"date-time":"2004-04-27T10:55:45Z","timestamp":1083063345000},"page":"267-280","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Tolterodine, a New Antimuscarinic Drug for Treatment of Bladder Overactivity"],"prefix":"10.1002","volume":"19","author":[{"given":"David R. P.","family":"Guay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,1,17]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1990.tb03503.x"},{"volume-title":"Urinary incontinence in adults: acute and chronic management","year":"1992","author":"Agency for Health Care Policy and Research","key":"e_1_2_1_3_2"},{"volume-title":"Urinary incontinence in adults: acute and chronic management","year":"1996","author":"Fantl JA","key":"e_1_2_1_4_2"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00578-5"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930070502"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00623-7"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00595-5"},{"key":"e_1_2_1_9_2","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0031-6997(25)06957-1","article-title":"Muscarinic receptor subtypes and smooth muscle function","volume":"48","author":"Eglen RM","year":"1996","journal-title":"Pharmacol Rev"},{"volume-title":"Data on file","year":"1998","author":"Pharmacia","key":"e_1_2_1_10_2"},{"key":"e_1_2_1_11_2","first-page":"308","article-title":"Pharmacological in vitro and in vivo profile of DD01\u2014a major metabolite of tolterodine [abstr]","volume":"15","author":"Gillberg P\u2010G","year":"1996","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_1_12_2","first-page":"523","article-title":"Interaction of tolterodine with cholinergic muscarinic receptors in human detrusor [abstr]","volume":"14","author":"Nilvebrant L.","year":"1995","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_1_13_2","first-page":"433","article-title":"The in vitro pharmacological profile of tolterodine\u2014a new agent for the treatment of urinary urge incontinence [abstr]","volume":"13","author":"Nilvebrant L.","year":"1994","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(97)89661-6"},{"key":"e_1_2_1_15_2","first-page":"435","article-title":"Tolterodine is not subtype (m1\u2010m5) selective but exhibits functional bladder selectivity in vivo [abstr]","volume":"15","author":"Nilvebrant L.","year":"1996","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_1_16_2","first-page":"435","article-title":"Tolterodine\u2014a new agent with tissue effect selectivity for urinary bladder [abstr]","volume":"13","author":"Gillberg P\u2010G","year":"1994","journal-title":"Neurourol Urodyn"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00057-X"},{"key":"e_1_2_1_18_2","first-page":"524","article-title":"Effect of tolterodine on electrically induced contractions of isolated human detrusor muscle from stable and unstable bladders [abstr]","volume":"14","author":"Naerger H.","year":"1995","journal-title":"Neurourol Urodyn"},{"volume-title":"Detrol (tolterodine) package insert","year":"1998","author":"Pharmacia","key":"e_1_2_1_19_2"},{"key":"e_1_2_1_20_2","first-page":"287","article-title":"Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity","volume":"35","author":"Brynne N.","year":"1997","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"4","key":"e_1_2_1_21_2","first-page":"394A","article-title":"Effects of tolterodine on bladder function in healthy volunteers [abstr]","volume":"153","author":"Ekstrom B.","year":"1995","journal-title":"J Urology"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.1930140606"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00599-2"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00501.x"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02201987"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00717.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1998.tb03830.x"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1592%2Fphco.19.4.267.30943","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1592\/phco.19.4.267.30943","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:12:19Z","timestamp":1761052339000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1592\/phco.19.4.267.30943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,3]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,3]]}},"alternative-id":["10.1592\/phco.19.4.267.30943"],"URL":"https:\/\/doi.org\/10.1592\/phco.19.4.267.30943","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[1999,3]]},"assertion":[{"value":"2012-01-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}